Abstract
Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Current Pharmaceutical Design
Title: KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin
Volume: 13 Issue: 28
Author(s): Juan J. Calvete, Cezary Marcinkiewicz and Libia Sanz
Affiliation:
Keywords: extracellular matrix, integrin inhibitor, synthetic RGD peptides, obtustatin, viperistatin
Abstract: Integrins α1β1 and α2β1 are highly expressed on the microvascular endothelial cells, and blocking of their adhesive properties significantly reduced the VEGF-driven neovascularization ratio and tumor growth in animal models. Hence, inhibitors of the α1β1 and α2β1 integrins, alone or in combination with antagonists of other integrins involved in angiogenesis (eg. αvβ3, αvβ5, and α6β4), may prove benefitial in the control of tumor neovascularization. Viperidae snakes have developed in their venoms an efficient arsenal of integrin receptor antagonists. KTS- (obtustatin, viperistatin, lebestatin) and RTS- (jerdostatin) disintegrins represent viper venom peptides that specifically block the interaction of the α1β1 integrin with collagens IV and I in vitro and angiogenesis in vivo. The possible therapeutic approach towards tumor neovascularization by targeting the α5β1, αvβ5 and αvβ3 integrins with RGD-bearing disintegrins has been explored in a number of laboratories. Here we discuss structure-function correlations of the novel group of specific (K/R)TS-disintegrins targeting the α1β1 integrin.
Export Options
About this article
Cite this article as:
Calvete J. Juan, Marcinkiewicz Cezary and Sanz Libia, KTS and RTS-Disintegrins: Anti-Angiogenic Viper Venom Peptides Specifically Targeting the α1β 1 Integrin, Current Pharmaceutical Design 2007; 13 (28) . https://dx.doi.org/10.2174/138161207782023766
DOI https://dx.doi.org/10.2174/138161207782023766 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles for Serotonin in Neurodevelopment: More than just Neural Transmission
Current Neuropharmacology Control of Menopausal Transition through Physical Exercises
Current Women`s Health Reviews Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Recent Developments in Pharmacologic Prophylaxis of Atrial Fibrillation in Patients Undergoing Surgical Revascularization
Cardiovascular & Hematological Agents in Medicinal Chemistry Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Effects of Remifentanil on the Cardiac Conduction System. Our Experience in the Study of Remifentanil Electrophysiological Properties
Current Pharmaceutical Design The Na+/Ca2+ Exchanger Mediates the Effects of Oxidative Stress in Hypertension
Current Hypertension Reviews Atheroprotective Properties of Pigment Epithelium-Derived Factor (PEDF) in Cardiometabolic Disorders
Current Pharmaceutical Design Impact of Aging on the Angiogenic Potential of the Myocardium: Implications for Angiogenic Therapies with Emphasis on Sirtuin Agonists
Recent Patents on Cardiovascular Drug Discovery Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Regenerative Therapies for Improving Myocardial Perfusion in Patients with Cardiovascular Disease: Failure to Meet Expectations but Optimism for the Future
Current Vascular Pharmacology PET Imaging of Beta-Adrenoceptors in Human Brain: A Realistic Goal or a Mirage?
Current Pharmaceutical Design Na+/Ca2+ Exchange Inhibitors: A New Class of Calcium Regulators
Cardiovascular & Hematological Disorders-Drug Targets Quercetin in Attenuation of Ischemic/Reperfusion Injury: A Review
Current Molecular Pharmacology Targeting Inflammation in Primary Cardiovascular Prevention
Current Pharmaceutical Design Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology CYP Epoxygenase Derived EETs: From Cardiovascular Protection to Human Cancer Therapy
Current Topics in Medicinal Chemistry